Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Seikagaku Wins US Patent Suit over Joint Function Improver
August 15, 2012
- Nichi-Iko to Shift to 2-Headquarters System in Oct.
August 15, 2012
- Otsuka HD’s April-June Pharma Sales Up 2.7% Despite Decline in Abilify Sales
August 15, 2012
- RaQualia Representative Director Nagahisa Steps Down, Mr Tani Appointed New Representative Director
August 15, 2012
- Over 20% of Doctors Report Decline in Meetings with MRs Since Revision of Business Entertainment GLs in April: CareNet Survey
August 13, 2012
- Business Strategies of Generics Manufacturers Become Evident Ahead of Upcoming Round of Patent Expiries
August 13, 2012
- Asahi Kasei in Hot Pursuit of Eli Lilly Japan as Competition Heats Up in Market for Bone Formation Agents
August 13, 2012
- Astellas Concludes Marketing Agreement with Nippon Kayaku for Vascular Embolization Material
August 10, 2012
- Takeda Terminates PIII Trial for AMG 479 for Pancreatic Cancer in Japan
August 10, 2012
- Up to 50% of Doctors Know About “Established Products” as Recognition Levels Rise: Pfizer Survey
August 9, 2012
- Mylan Transfers Exclusive Rights to Pfizer to Market EpiPen in Japan
August 9, 2012
- Shionogi’s Korean Partner Obtains Approval for Pirespa
August 9, 2012
- Astellas Applies for Irribow OD Tablet
August 9, 2012
- Ethical Drug Sales Down 0.3% in June: Crecon Report
August 8, 2012
- Hospira Files Additional Indication for Precedex for Non-Intubated Patients
August 8, 2012
- Daiichi Sankyo to Strengthen Cardiovascular Field by Comarketing Diabetes Treatments, Focusing on SGLT-2 Inhibitor
August 8, 2012
- 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
- Astellas to Close US Subsidiary for Urology Research
August 7, 2012
- Fuji Pharma to Acquire Thailand’s Largest Contract Manufacturer, to Make It Base of Overseas Operations
August 7, 2012
- Japan BCG Laboratory, Nippon Kayaku to Copromote Immunobladder
August 7, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…